Antihypertensive and renoprotective effect of the kinin pathway activated by potassium in a model of salt sensitivity following overload proteinuria

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 12, 2013, Pages 1399-1410

  Ardiles, Leopoldo ^a   Cardenas, Areli ^a   Burgos, María E ^a   Droguett, Alejandra ^a   Ehrenfeld, Pamela ^a   Carpio, Daniel ^a   Mezzano, Sergio ^a   Figueroa, Carlos D ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

Bradykinin; Kallikrein; Potassium; Receptor; Renoprotection; TGF

Indexed keywords

ACEDAPSONE; BRADYKININ; CREATININE; KALLIKREIN; KININ; MESSENGER RNA; POTASSIUM; TISSUE KALLIKREIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GLOMERULOSCLEROSIS; HIGH POTASSIUM INTAKE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY FUNCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

EID: 84879142116     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00604.2012     Document Type: Article

References (63)

1. Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224: 625-630, 1996.
2. Alvarez V, Quiroz Y, Nava M, Pons H, Rodriguez-Iturbe B. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 283: F1132-F1141, 2002.
3. Amundsen E, Putter J, Friberger P, Knos M, Larsbraten M, Claeson G. Methods for the determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv Exp Med Biol 120A: 83-95, 1979.
4. Ardiles LG, Ehrenfeld P, Quiroz Y, Rodriguez-Iturbe B, Herrera-Acosta J, Mezzano S, Figueroa CD. Effect of mycophenolate mofetil on kallikrein expression in the kidney of 5/6 nephrectomized rats. Kidney Blood Press Res 25: 289-295, 2002.
5. Ardiles LG, Loyola F, Ehrenfeld P, Burgos ME, Flores CA, Valder-rama G, Caorsi I, Egido J, Mezzano SA, Figueroa CD. Modulation of renal kallikrein by a high potassium diet in rats with intense proteinuria. Kidney Int 69: 53-59, 2006.
6. Barajas L, Powers K, Carretero O, Scicli AG, Inagami T. Immunocy-tochemical localization of renin and kallikrein in the rat renal cortex. Kidney Int 29: 965-970, 1986.
7. Blaes N, Pecher C, Mehrenberger M, Cellier E, Praddaude F, Chevalier J, Tack I, Couture R, Girolami JP. Bradykinin inhibits high glucose- and growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor. Am J Physiol Renal Physiol 303: F293-F303, 2012.
8. Bledsoe G, Crickman S, Mao J, Xia CF, Murakami H, Chao L, Chao J. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 21: 624-633, 2006.
9. Bliss DJ, Brewer DB. Ultrastructural localization of anionic and cationic ferritin in the rat glomerular basement membrane in protein-overload proteinuria. J Pathol 143: 57-68, 1984.
10. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R, Sanchez-Lopez E, Ruperez M, Cartier C, Esteban V, Ortiz A, Egido J, Mezzano SA, Ruiz-Ortega M. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 74: 585-595, 2008.
11. Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 90: 291-298, 2005.
12. Chao J, Zhang JJ, Lin KF, Chao L. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 54: 1250-1260, 1998.
13. Chao J, Zhang JJ, Lin KF, Chao L. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 9: 21-31, 1998.
14. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol 289: F227-F234, 2005.
15. Davies DJ, Brewer DB. Irreversible glomerular damage following heter-ologous serum albumin overload. J Pathol 123: 45-52, 1977.
16. Eddy AA. Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 135: 719-733, 1989.
17. Eddy AA. Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. Kidney Int Suppl 54: S49-S54, 1996.
18. El MS, Houillier P, Picard N, Sohet F, Wootla B, Bloch-Faure M, Leviel F, Cheval L, Frische S, Meneton P, Eladari D, Chambrey R. Tissue kallikrein permits early renal adaptation to potassium load. Proc Natl Acad Sci USA 107: 13526-13531, 2010.
19. Eladari D, Chambrey R, Peti-Peterdi J. A new look at electrolyte transport in the distal tubule. Annu Rev Physiol 74: 325-349, 2012.
20. Ellis D, Banner B, Janosky JE, Feig PU. Potassium supplementation attenuates experimental hypertensive renal injury. J Am Soc Nephrol 2: 1529-1537, 1992.
21. Erdos EG, Yamada K. Prekallikrein, kallikrein and renin in membrane fractions of rat kidney. Clin Exp Hypertens A 4: 2083-2096, 1982.
22. Faarup P. On the morphology of the juxtaglomerular apparatus. Acta Anat (Basel) 60: 20-38, 1965.
23. Fujita T, Sato Y, Ando K. Role of sympathetic nerve activity and natriuresis in the antihypertensive actions of potassium in NaCl hypertension. Jpn Circ J 47: 1227-1231, 1983.
24. Hinks GL, Franklin RJ. Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-beta1 gene expression during remyelination of experimentally-induced spinal cord demyelination. Mol Cell Neurosci 14: 153-168, 1999.
25. Hirawa N, Uehara Y, Suzuki T, Kawabata Y, Numabe A, Gomi T, lkeda T, Kizuki K, Omata M. Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Nephron 81: 183-193, 1999.
26. Horwitz D, Margolius HS, Keiser HR. Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J Clin Endocrinol Metab 47: 296-299, 1978.
27. Ibrini J, Fadel S, Chana RS, Brunskill N, Wagner B, Johnson TS, El Nahas AM. Albumin-induced epithelial mesenchymal transformation. Nephron Exp Nephrol 120: e91-e102, 2012.
28. Jin L, Chao L, Chao J. Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. Am J Physiol Renal Physiol 276: F476-F484, 1999.
29. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, Hua K, Gasim AM, Tomita H, Grant R, Nossov SB, Kim HS, Jennette JC, Feldman EL, Smithies O. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci USA 107: 10190-10195, 2010.
30. Katori M, Majima M. Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn J Pharmacol 70: 95-128, 1996.
31. Katori M, Majima M. The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit Rev Clin Lab Sci 40: 43-115, 2003.
32. Largo R, Gomez-Garre D, Soto K, Marron B, Blanco J, Gazapo RM, Plaza JJ, Egido J. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 33: 732-739, 1999.
33. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 21: 212-222, 2010.
34. Majima M, Yoshida O, Mihara H, Muto T, Mizogami S, Kuribayashi Y, Katori M, Oh-ishi S. High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats. Hypertension 22: 705-714, 1993.
35. Martinez-Maldonado M. Role of hypertension in the progression of chronic renal disease. Nephrol Dial Transplant 16, Suppl 1: 63-66, 2001.
36. Obika LF. Urinary kallikrein excretion after potassium adaptation in the rat. Arch Int Physiol Biochim 95: 189-193, 1987.
37. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666, 1988.
38. Peralta-Zaragoza O, Lagunas-Martinez A, Madrid-Marina V. Transforming growth factor beta-1: structure, function, and regulation mechanisms in cancer. Salud Publica Mex 43: 340-351, 2001.
39. Popp R, Bauersachs J, Hecker M, Fleming I, Busse R. A transferable, beta-naphthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells. J Physiol 497: 699-709, 1996.
40. Rodriguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59: 2222-2232, 2001.
41. Roson MI, la Penna SL, Cao G, Gorzalczany S, Pandolfo M, Cerrudo C, Fernandez BE, Toblli JE. High-sodium diet promotes a profibrogenic reaction in normal rat kidneys: effects of Tempol administration. J Nephrol 24: 119-127, 2011.
42. Salvemini D, Seibert K, Masferrer JL, Misko TP, Currie MG, Needle-man P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 93: 1940-1947, 1994.
43. Sato Y, Fujita T, Yamashita K. Antihypertensive action of K in rats with DOCA-salt-induced hypertension. Nihon Yakurigaku Zasshi 82: 117-130, 1983.
44. Schanstra JP, Neau E, Drogoz P, Revalo Gomez MA, Lopez Novoa JM, Calise D, Pecher C, Bader M, Girolami JP, Bascands JL. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110: 371-379, 2002.
45. Siragy HM. Evidence that intrarenal bradykinin plays a role in regulation of renal function. Am J Physiol Endocrinol Metab 265: E648-E654, 1993.
46. Siragy HM, Ibrahim MM, Jaffa AA, Mayfield R, Margolius H.S. Rat renal interstitial bradykinin, prostaglandin E2, and cyclic guanosine 3=,5=-monophosphate. Effects of altered sodium intake. Hypertension 23: 1068-1070, 1994.
47. Stanton BA. Characterization of apical and basolateral membrane conductances of rat inner medullary collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 256: F862-F868, 1989.
48. Tanaka Y, Nagai M, Date T, Okada T, Abe Y, Seki S, Taniguchi M, Taniguchi I, Mochizuki S. Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 27: 865-875, 2004.
49. Tu L, Xu X, Wan H, Zhou C, Deng J, Xu G, Xiao X, Chen Y, Edin ML, Voltz JW, Zeldin DC, Wang DW. Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther 19: 318-330, 2008.
50. Valdes G, Figueroa CD, Corthorn J. Temporospatial changes of kal-likrein-like enzymes during the estrous cycle and pregnancy in the rat uterus. Biol Reprod 55: 236-245, 1996.
51. Vio CP, Figueroa CD. Evidence for a stimulatory effect of high potassium diet on renal kallikrein. Kidney Int 31: 1327-1334, 1987.
52. Vio CP, Figueroa CD, Caorsi I. Anatomical relationship between kal-likrein-containing tubules and the juxtaglomerular apparatus in the human kidney. Am J Hypertens 1: 269-271, 1988.
53. Wang D, Yoshida H, Song Q, Chao L, Chao J. Enhanced renal function in bradykinin B2 receptor transgenic mice. Am J Physiol Renal Physiol 278: F484-F491, 2000.
54. Wang W, Soltero L, Zhang P, Huang XR, Lan HY, Adrogue HJ. Renal inflammation is modulated by potassium in chronic kidney disease: possible role of Smad7. Am J Physiol Renal Physiol 293: F1123-F1130, 2007.
55. Wolf WC, Yoshida H, Agata J, Chao L, Chao J. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 58: 730-739, 2000.
56. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 159: 1465-1475, 2001.
57. Ying WZ, Sanders PW. Dietary salt modulates renal production of transforming growth factor-(3 in rats. Am J Physiol Renal Physiol 274: F635-F641, 1998.
58. Ying WZ, Sanders PW. Dietary salt increases endothelial nitric oxide synthase and TGF-(31 in rat aortic endothelium. Am J Physiol Heart Circ Physiol 277: H1293-H1298, 1999.
59. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnston CI. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98: 2621-2628, 1998.
60. Zhang JJ, Bledsoe G, Kato K, Chao L, Chao J. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66: 722-732, 2004.
61. Zhang XL, Selbi W, de la MC, Hascall V, Phillips A. Renal proximal tubular epithelial cell transforming growth factor-beta1 generation and monocyte binding. Am J Pathol 165: 763-773, 2004.
62. Zoja C, Benigni A, Remuzzi G. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 7: 420-428, 1999.
63. Zoja C, Perico N, Bergamelli A, Pasini M, Morigi M, Dadan J, Belloni A, Bertani T, Remuzzi G. Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney Int 37: 934-942, 1990.